Diabetes news diabetes research




Researchers at the University of

Nottingham's School of Pharmacy have

designed and tested large molecular

complexes that will reveal their true

identity only when they've reached their

intended target. The compounds have

been developed as part of a five-year

programme funded by the Engineering

and Physical Sciences Research Council

(EPSRC) called "Bar-Coded Materials".

Each spherical complex has a

sheath of biocompatible polymer that

encapsulates and shrouds biologically

active material inside, preventing any

biological interaction -- so long as the

shield remains in place.

The smart aspect is DNA-based zips

that hold the coat in place until triggered

to undo. Because any DNA code (or

"molecular cipher") can be chosen, the

release mechanism can be bar-coded so

that it is triggered by a specific biomarker

- for example, a message from a disease

gene. What is then exposed - an active

pharmaceutical compound, a molecular

tag to attach to diseased tissue, or a

molecular beacon to signal activation -

depends on what function is needed.

Professor Cameron Alexander, who

has been leading the project, says: "These

types of switchable nanoparticles could

be extremely versatile. As well as initial

detection of a medical condition, they

could be used to monitor the progress

of diseases and courses of treatment,

or adapted to deliver potent drugs at

particular locations in a patient's body. It

might even become possible to use mobile

phones rather than medical scanners to

detect programmed responses from later

generations of the devices."

The team's new results have been

published in Nanoscale; the full article can

be downloaded here.


As reported by Brenda Neugent in Diabetes

Health, a study gauging the benefits of

the diet drug Qsymia showed that those

who took the drug not only lost weight,

but also saw their HbA1c levels improve,

even if they didn't have diabetes. The

results of the 56-week study on the weight

loss of those taking extended-release

Qsymia were reported at the recent World

Congress on Insulin Resitance, Diabetes

and Cardiovascular Disease.

Those taking a low dose of the drug

lost from 6.8-8.9% of their body weight,

while those taking a high dose lost

between 8.8-11% of their body weight,

according to Dr. Tim Garvey of the

University of Alabama at Birmingham, and

colleagues who conducted the study.

Qysmia is made of two different

drugs, phentermine, which is in a

drug class similar to amphertamines

and is recommended as an appetite

suppressant, and topiramate, a drug

that has been traditionally used to treat

epilepsy, bipolar disorder, and migraines,

though it was approved in 2012 to be

used with phentermine as a weight-loss

drug. However, according America's

FDA (Food and Drug Administration),

Qysmia can cause birth defects if taken

during pregnancy, elevated heart rate,

depression, changes in mood or suicidal

thoughts, and serious eye problems that

could result in permanent vision loss.




NovoRapid PumpCart is to be marketed

in Europe. The 1.6 ml prefilled insulin

pump cartridge contains the rapid-acting

NovoRapid insulin and is compatible with

Roche Diabetes Care's next-generation

Accu-Chek Insight diabetes therapy


NovoRapid PumpCart has been

developed in a non-exclusive partnership

between Roche Diabetes Care, a

pioneer and global market leader in the

development of diabetes management

solutions and services, and Novo

Nordisk, a world leader in diabetes care.

The prefilled cartridge and insulin delivery

system should make insulin pump therapy

more convenient as it means you do

longer need to fill up insulin reservoirs

from insulin bottles.

"Now, insulin pump users can simply

place a prefilled insulin cartridge into their

insulin pump without any extra handling

steps. Novo Nordisk is committed to

improving diabetes care, so we are

pleased to provide pump users with this

new treatment option", says Jakob Riis,

executive vice president, Marketing and

Medical Affairs, Novo Nordisk.

Luc Vierstraete, Global Head of

Roche Diabetes Care, adds: "We are

excited to be able to offer this solution to

our customers and bring to market our

innovative Accu-Chek Insight diabetes

therapy system compatible with the

option of using the new prefilled insulin

cartridge. This can help to enhance the

advantages of a targeted and effective

insulin pump therapy while contributing

to a simplified diabetes management in

everyday life."

NovoRapid PumpCart will be launched

during 2014 and 2015.


  1. Desang diabetes magazine diabetes information
  2. Bayer Contour Link USB blood test meter for Medtronic insulin pump
  3. Desang diabetes magazine diabetes information
  4. Diabetes kit diabetes management equipment
  5. Medtronic Enlite CGM sensor special offer
  6. Diabetes food news and diabetic diet
  7. Accu-Chek blood test meters
  8. Diabetes News
  9. Diabetes news, Diabetes ressearch
  10. Desang diabetes kitbag clearance, diabetes research opportunity
  11. Page 0011
  12. Diabetes news diabetes research
  13. Action on Sugar and diabetes
  14. Action on Sugar and diabetes
  15. Action on Sugar
  16. honey and diabetes
  17. honey and diabetes
  18. honey and diabetes
  19. honey and diabetes
  20. Honey and diabetes
  21. Accu-Chek Combo insulin pump, insulin pumps, insulin infusion sets
  22. desang diabetes kitbags

Related Issues